So sánh phương pháp
Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.
| Quality-Adjusted Life Year (QALY)× | Mô hình chuỗi Markov trong kinh tế y tế× | |
|---|---|---|
| Lĩnh vực | Kinh tế học y tế | Kinh tế học y tế |
| Họ | Process / pipeline | Process / pipeline |
| Năm ra đời≠ | 1985 | 1983 |
| Người khởi xướng≠ | Alan Williams (Health Economics Research Centre, Oxford University) | Beck & Pauker (medical decision analysis, Massachusetts General Hospital) |
| Loại | Method | Method |
| Công trình gốc≠ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ | Beck, J. R., & Pauker, S. G. (1983). The Markov Process in Medical Prognosis. Medical Decision Making, 3(4), 419-458. DOI ↗ |
| Tên gọi khác≠ | QALY, health utility measure | Markov model, state transition model, cohort simulation |
| Liên quan | 5 | 5 |
| Tóm tắt≠ | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. | A Markov model is a decision-analytic tool that simulates disease progression through defined health states over time, calculating cumulative costs and quality-adjusted life years (QALYs) to enable cost-effectiveness analysis. Developed by Beck and Pauker in 1983, Markov models are now the standard framework for projecting long-term outcomes of health interventions, especially chronic diseases where patients transition between clinical states (treatment response, disease progression, remission, death). Used by health technology assessment bodies and pharmaceutical companies to predict intervention value beyond trial duration. |
| ScholarGateBộ dữ liệu ↗ |
|
|